Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors:a new regimen for locally advanced non-small cell lung cancer?

作     者：Lin Ma Liufu Deng Jianfeng Peng Jinming Yu Xiangjiao Meng Lin Ma;Liufu Deng;Jianfeng Peng;Jinming Yu;Xiangjiao Meng

作者机构：Department of OncologyRenmin Hospital of Wuhan UniversityWuhan 430000China Department of Radiation OncologyShandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinan 250117China School of PharmacyShanghai Jiao Tong UniversityShanghai 200240China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2023年第20卷第12期

页      面：1035-1046页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 

基　　金：funded by the National Natural Science Foundation of China(Grant Nos.81972796,82272845,81972863,and 82030082) the Key Research and Development Program of Shandong(Major Science&Technology Innovation Project Grant No.2021SFGC0501) the CSCO-Haosen Foundation(Grant No.Y-HS202102-0089) the CSCO-Xinda Foundation(Grant No.Y-XD202001-0008) 

主　　题：Locally advanced non-small cell lung cancer(LA-NSCLC) radiotherapy immunotherapy new regimen challenges 

摘      要：Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer(LA-NSCLC).The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for *** recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy(i RT)have generated encouraging *** review discusses the existing studies and prospective directions of chemotherapy-free i RT strategies in unresectable *** the initial findings of chemotherapy-free i RT strategies have shown promising efficacy,we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free i *** challenges include determining the optimal dose and fractionation,precise target volume delineation,and identification of additional suitable patient ***,the feasibility of chemotherapy-free i RT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials.